Compared side by side
GHK-Cu vs KPV: how they differ
The short answer
GHK-Cu is a copper-binding tripeptide found naturally in human plasma and widely used in skincare; in cell and animal studies it boosts collagen and speeds wound repair. KPV is also three amino acids long, the tail end of α-MSH, and in cell and mouse studies it calms inflammation by blocking NF-κB inside cells. Commonly reported: smoother skin texture and a more even tone after a month or two of GHK-Cu, and a calmer gut and calmer skin on KPV.
Side by side
| Compared | GHK-Cu | KPV |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Copper Peptide, GHK-Copper, Tripeptide-1 | Lys-Pro-Val, α-MSH tripeptide |
| What it is | A small copper-binding peptide found naturally in your blood and widely used in skincare. | One of the smallest bioactive peptides: three amino acids from the tail end of α-MSH. |
| How it works | Tripeptide (glycyl-histidyl-lysine) that binds a copper(II) ion. It occurs naturally in human plasma, and its sequence sits inside type I collagen and the tissue-remodeling protein SPARC. In cell and animal studies, GHK-Cu increased collagen, decorin and glycosaminoglycan production, raised VEGF output by fibroblasts, and damped inflammatory signals such as IL-6. Human evidence is limited to a handful of topical trials, most of them small. | C-terminal tripeptide of α-MSH. A potent anti-inflammatory in cell and mouse studies that works mainly inside cells rather than through melanocortin receptors: it enters through the PepT1 transporter and blocks NF-κB signaling. In mice it eased colitis and damped allergic skin reactions; as eye drops it sped corneal wound healing in rabbits; in lab dishes it slowed Staphylococcus aureus and Candida albicans. |
| Commonly reported | Smoother texture and a more even tone after a month or two. Injected GHK-Cu hasn't been tested in a controlled trial. | A calmer gut and calmer skin. No human study has tested it yet. |
| Studied range | Research range: 1–2 mg. Studied in research — not a recommendation. | Research range: 100–300 mcg. Studied in research — not a recommendation. |
| How often | Daily | Daily |
| Half-life | Not measured in humans (breaks down quickly in plasma in rat and lab studies) | Not measured: no half-life for KPV has been published, in people or animals |
| Route | SubQ injection, Topical application, IM injection | SubQ injection, Oral |
| Typical run | Often run 8–12 weeks. Can be cycled or run continuously at lower doses. Community consensus is loose. | 4–8 weeks typical for gut protocols. Can reassess after each cycle. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection site reaction, skin irritation (topical), mild flushing | Injection site irritation, mild nausea |
- Category
- GHK-CuHealing & recovery
- KPVHealing & recovery
- Also known as
- GHK-CuCopper Peptide, GHK-Copper, Tripeptide-1
- KPVLys-Pro-Val, α-MSH tripeptide
- What it is
- GHK-CuA small copper-binding peptide found naturally in your blood and widely used in skincare.
- KPVOne of the smallest bioactive peptides: three amino acids from the tail end of α-MSH.
- How it works
- GHK-CuTripeptide (glycyl-histidyl-lysine) that binds a copper(II) ion. It occurs naturally in human plasma, and its sequence sits inside type I collagen and the tissue-remodeling protein SPARC. In cell and animal studies, GHK-Cu increased collagen, decorin and glycosaminoglycan production, raised VEGF output by fibroblasts, and damped inflammatory signals such as IL-6. Human evidence is limited to a handful of topical trials, most of them small.
- KPVC-terminal tripeptide of α-MSH. A potent anti-inflammatory in cell and mouse studies that works mainly inside cells rather than through melanocortin receptors: it enters through the PepT1 transporter and blocks NF-κB signaling. In mice it eased colitis and damped allergic skin reactions; as eye drops it sped corneal wound healing in rabbits; in lab dishes it slowed Staphylococcus aureus and Candida albicans.
- Commonly reported
- GHK-CuSmoother texture and a more even tone after a month or two. Injected GHK-Cu hasn't been tested in a controlled trial.
- KPVA calmer gut and calmer skin. No human study has tested it yet.
- Studied range
- GHK-CuResearch range: 1–2 mg. Studied in research — not a recommendation.
- KPVResearch range: 100–300 mcg. Studied in research — not a recommendation.
- How often
- GHK-CuDaily
- KPVDaily
- Half-life
- GHK-CuNot measured in humans (breaks down quickly in plasma in rat and lab studies)
- KPVNot measured: no half-life for KPV has been published, in people or animals
- Route
- GHK-CuSubQ injection, Topical application, IM injection
- KPVSubQ injection, Oral
- Typical run
- GHK-CuOften run 8–12 weeks. Can be cycled or run continuously at lower doses. Community consensus is loose.
- KPV4–8 weeks typical for gut protocols. Can reassess after each cycle.
- Evidence
- GHK-CuEmerging: primarily preclinical / limited human data
- KPVEmerging: primarily preclinical / limited human data
- Common side effects
- GHK-CuInjection site reaction, skin irritation (topical), mild flushing
- KPVInjection site irritation, mild nausea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
GHK-Cu
- Day 1–14 The first two weeks are groundwork
- Day 14–28 Texture tends to move first
- Day 28–56 This is where results tend to show
- Day 56–84 Weeks 8–12: time for an honest look
- Day 84+ Past the studied window — your read now
KPV
- Day 1–7 Week one: your starting point
- Day 7–21 Users often report a calmer gut
- Day 21–42 Some report calmer skin
- Day 42–56 Weeks 6 to 8: taking stock
Together or one or the other
GHK-Cu and KPV are a common stack: they’re together in the KLOW stack.
- KLOW: GLOW plus KPV — four repair peptides in one vial (KPV, BPC-157, TB-500 and GHK-Cu).
Questions people ask
How long do GHK-Cu and KPV last?
The half-life of GHK-Cu is not measured in humans (breaks down quickly in plasma in rat and lab studies). The half-life of KPV is not measured: no half-life for KPV has been published, in people or animals.
How often are GHK-Cu and KPV taken?
GHK-Cu: daily. Routes: SubQ injection, topical application, IM injection. KPV: daily. Routes: SubQ injection, oral.
How are GHK-Cu and KPV dosed in research?
The research range for GHK-Cu is 1–2 mg. The research range for KPV is 100–300 mcg. Studied in research — not a recommendation.
What are the common side effects of GHK-Cu and KPV?
For GHK-Cu, the library lists: injection site reaction, skin irritation (topical), mild flushing. For KPV: injection site irritation, mild nausea.
Are GHK-Cu and KPV taken together?
GHK-Cu and KPV are a common stack: they’re together in the KLOW stack.